BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 4, 2024
See today's BioWorld Asia
Home
» Hong Kong's Aptorum signs $90M deal with Singapore's A*STAR to co-create ventures
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hong Kong's Aptorum signs $90M deal with Singapore's A*STAR to co-create ventures
May 1, 2019
By
David Ho
and
Cornelia Zou
No Comments
HONG KONG – Hong Kong-based companies Aptorum Group Ltd. and Aeneas Capital Ltd. have signed a $90 million deal with Singapore-based A*ccelerate Technologies Pte Ltd. to develop ventures in the health care and life sciences sector.
BioWorld Asia